Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Cruise worker 'murders newborn son on board ship': Shocked co
Palestinian death toll in Gaza rises to 34,488: ministry
Flying car maker plans to take orders this year
Olympic flame arrives in Marseille amid tight security
Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
Canadian Nobel Laureate Alice Munro dies at 92
Russia vetoes UN Security Council draft resolution on weapons of mass destruction in outer space
Arabic version of book about Xi's elaborations on BRI promoted in UAE
Iran helicopter crash that killed President Raisi could reverberate across the Middle East
WTA1000 Wuhan Open to return in October
The unstoppable duo of Emma Stone and Yorgos Lanthimos
China's 10th National Public Ice and Snow Season launched